Company targets confirmatory trials of immunomodulator shown to slow cognitive decline when used as a control arm.
Longevity biotech Advantage Therapeutics has secured a $2.5 million Phase II Small Business Innovation Research grant from the National Institute on Aging to advance its Alzheimer’s disease candidate AD04. The Miami-based biotech is preparing to launch confirmatory Phase 2b clinical trials in Europe to evaluate the therapy’s safety and efficacy in early-stage patients.
With a long history of use as a vaccine adjuvant in both human and animal programs, Advantage is repurposing AD04 as a new class of Alzheimer’s therapy with potential both for immediate symptomatic relief and for long-term disease modification. The drug’s existing safety profile will be key as Advantage pushes toward late-stage testing under Europe’s clinical trial authorization process and with support from the UK’s Innovative Licensing and Access Pathway (ILAP), which provides conditional approval after Phase 2 studies.
Commenting on the grant funding, Advantage CEO Jeffrey Madden, said: “This award positions us to accelerate regulatory momentum and attract the strategic partners required for broad patient access.”
AD04 functions as an immunomodulator, regulating the immune system to reduce disease pathology rather than directly targeting amyloid beta or tau proteins. Its activity has been linked to restoration of genes involved in lipid metabolism, improved phagocytosis, and reduced inflammation.
The compound first drew attention during a prior clinical study in which it was employed as a control arm against another drug. Patients receiving AD04 showed statistically slower decline in cognition, quality of life, and hippocampal volume compared with other treatment groups. These findings were recently reinforced in a publication in The Journal of Prevention of Alzheimer’s Disease, which included independent statistical analyses showing the effects were unlikely to be due to chance.
Further mechanistic insights were presented at the Alzheimer’s Association International Conference last year, suggesting AD04 restores expression of key proteins involved in lipid metabolism, which may underpin both its symptomatic and disease-modifying benefits. In animal models, the treatment aligned the lipid protein expression profiles of aged mice with those of younger animals, highlighting its potential impact on hippocampal function.
Last year, Advantage launched Klothea Bio, a subsidiary dedicated to therapies targeting klotho, a protein linked to longevity and resilience against age-related decline. Klothea is pursuing mRNA-based approaches to restore youthful levels of the protein, beginning with studies in metabolic syndrome and expanding to neurodegenerative diseases, cancer, and other conditions.
